Hoth’s GDNF Cuts Weight Gain by 10–15% vs Novo’s Semaglutide, Threatens $200B Market
Hoth Therapeutics' experimental GDNF outperformed Novo Nordisk's semaglutide in preclinical female mice, reducing weight gain by 10-15%, normalizing fasting glucose and cutting liver weight by 20-30%. Its multi-faceted efficacy against diet-induced obesity and MASLD threatens to disrupt the $200 billion obesity market dominated by Novo's Wegovy and Ozempic.
1. Preclinical GDNF vs Semaglutide Results
In a head-to-head preclinical trial in female mice, GDNF reduced weight gain by 10-15%, fully normalized fasting glucose and cut liver weight by 20-30%, outperforming semaglutide across key metabolic metrics.
2. Potential Impact on Novo Nordisk
These data introduce GDNF as a potential challenger to Novo Nordisk’s Wegovy and Ozempic, putting pressure on the company’s position in the $200 billion obesity and MASLD treatment market.
3. Hoth’s Development Timeline
Backed by the U.S. Veterans Administration, Hoth plans IND-enabling studies in 2026 and aims to begin clinical trials in 2027 to advance GDNF toward regulatory approval.